Constitutively Active vs Dominant-Negative: Mutation Logic at the Receptor Layer

Path Outline

Progress0%

1Exam Surface Mapping From a Syllabus or Fallback Blueprint 2A Minimal Signal-Flow Grammar for Mechanistic Tracing 3Perturbation-to-Readout Prediction With Directional Logic 4Readout Vocabulary and the Activation-vs-Abundance Trap 5Conceptual Figure Sprints: Claims, Controls, and Permissible Conclusions

6Two Receptor Classes, Two Proximal Chemistries 7RTK Autophosphorylation and Docking-Site Logic 8GPCR–G Protein Switching: Gs vs Gi and Proximal Predictions 9Interaction Modules and Recruitment Decisions at the Membrane

10Constitutively Active vs Dominant-Negative: Mutation Logic at the Receptor Layer

11Protein Naming and Function Checks With NCBI Gene and UniProt 12Receptor-Layer Crosstalk as Shared Nodes and Context Dependence 13Phospho vs Total at the Receptor: A Proximal Figure Sprint

14cAMP as a Fast Amplifier: From G Proteins to PKA and Termination 15Gs vs Gi Logic: When cAMP Goes Up, Down, or Appears to Invert 16PLC Splits PIP2: IP3 for Ca2+ Release and DAG for PKC 17Perturbing the Fork: IP3 Receptor Block, Ca2+ Chelation, and PKC Inhibition 18Ca2+ and Calmodulin: Turning a Transient Ion Signal Into Enzyme Control 19Timing and Readouts: Second Messenger Spikes vs Transcriptional Responses 20Exam Traps, Readout Mapping, and a Bridge to Kinase Cascades

21MAPK/ERK Wiring and Phospho-Node Predictions 22Ras as a Molecular Switch: Mutations and Signal Lock-In 23PI3K/Akt Signaling and PTEN as a Brake 24Akt Outputs: Growth and Survival Tendencies Without Full Fate Pathways 25JAK/STAT: From Receptor-Associated Kinases to Nuclear STAT Dimers 26Crosstalk and Feedback: When PI3K Inhibition Changes ERK 27Pathway Databases as Scaffolds, Not Answers 28Inhibitor and Readout Caveats: Off-Target Effects, Controls, and Timing 29HER2/ERBB2 Amplification as Increased RTK Drive Into MAPK and PI3K

30Transcription Factor State as the Bridge From Signaling to Gene Expression 31Choosing the Right Measurement Layer for Gene-Expression Claims 32miRNA Repression and Protein-First Changes Without Big mRNA Shifts 33siRNA Knockdown Logic Versus Genome Editing at the Claim Level 34lncRNA as Regulatory Scaffold: What Would Count as Evidence?35Biomolecular Condensates as Spatial Organizers of Transcription 36Evidence-First Mini-Synthesis: pERK Versus Total ERK and What Nuclear Output Claims Survive

37The Cell Cycle as a Checkpointed State Machine 38DNA Damage Signaling and Checkpoint Arrest Predictions 39Oncogene Drive vs Tumor Suppressor Enforcement as an Inference Frame 40Growth and Survival Signaling Inputs Into Cell-Cycle Entry 41DNA-Content Histograms as Evidence: What Shifts Mean and What They Don’t 42Timing and Indirect Effects in Cell-Cycle Experiments 43Perturbation Panels: Growth Factor Plus CDK Inhibitor Predictions

44Extrinsic vs Intrinsic Apoptosis: Two Initiation Graphs 45Caspase Cascades as Amplifiers: Commitment and Timing 46Mitochondrial Commitment and BCL-2 Balance Logic 47PI3K/Akt Survival Signaling as an Anti-Apoptotic Bias 48Conceptual Flow Readouts for Apoptosis: Percent-Positive vs Intensity 49Competing Inputs: Arrest, Repair, or Apoptosis Under Combined Perturbations 50Apoptosis Inference Traps: Viability, Pathway Claims, and Direct Interaction

51Rate Laws to Michaelis–Menten Curves: What Vmax and Km Actually Control 52Inhibition Type From Plot Shifts: Competitive vs Noncompetitive 53Lineweaver–Burk Plots: A Diagnostic Tool With Real Limits 54Western Blots as Evidence: Loading, Total Protein, and Phospho Controls 55Activation State vs Abundance: The “Phospho Band Up” Trap 56Time-Course Blots: Order of Events and Control Lanes 57Flow Cytometry Histograms: Percent-Positive, MFI Shifts, and Bimodality 58Co-IP Evidence: Complex Association, Controls, and Overreach 59FRAP Recovery Curves: Mobility, Turnover, and the Phase-Separation Overclaim 60CRISPR Modalities, Epistasis-Style Rescue Logic, and Mixed Data Synthesis

Hide outline

Home
Paths
Mechanistic Cell and Molecular Biology for Exam Performance: Signaling to Transcription, Cell Fate,
Constitutively Active vs Dominant-Negative: Mutation Logic at the Receptor Layer